Moving beyond immunoglobulin therapy for CIDP with efgartigimod.
作者信息
Lünemann Jan D
机构信息
Department of Neurology with Institute of Translational Neurology, University and University Hospital of Münster, Münster, Germany.
出版信息
Nat Rev Neurol. 2025 Jan;21(1):1-2. doi: 10.1038/s41582-024-01045-8.
PMID:39609632
Abstract
摘要
相似文献
1
Moving beyond immunoglobulin therapy for CIDP with efgartigimod.超越使用艾加莫德进行慢性炎症性脱髓鞘性多发性神经病的免疫球蛋白治疗。
Nat Rev Neurol. 2025 Jan;21(1):1-2. doi: 10.1038/s41582-024-01045-8.
2
Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial.皮下注射依氟鸟氨酸在慢性炎症性脱髓鞘性多发性神经病（ADHERE）患者中的安全性、耐受性和疗效：一项多中心、随机撤药、双盲、安慰剂对照、2 期临床试验。
Lancet Neurol. 2024 Oct;23(10):1013-1024. doi: 10.1016/S1474-4422(24)00309-0.
3
Safety profile of efgartigimod from global clinical trials across multiple immunoglobulin G-mediated autoimmune diseases.在多种免疫球蛋白G介导的自身免疫性疾病的全球临床试验中，艾加莫德的安全性概况。
Expert Rev Clin Immunol. 2025 May;21(5):627-638. doi: 10.1080/1744666X.2025.2497840. Epub 2025 May 13.
4
Early deterioration of CIDP following transition from IVIG to FcRn inhibitor treatment.从静脉注射免疫球蛋白（IVIG）过渡到FcRn抑制剂治疗后慢性炎性脱髓鞘性多发性神经病（CIDP）的早期恶化。
J Neurol Sci. 2025 Jan 15;468:123313. doi: 10.1016/j.jns.2024.123313. Epub 2024 Nov 17.
5
Efgartigimod as a novel FcRn inhibitor for autoimmune disease.艾加莫德作为一种用于自身免疫性疾病的新型FcRn抑制剂。
Neurol Sci. 2024 Sep;45(9):4229-4241. doi: 10.1007/s10072-024-07460-5. Epub 2024 Apr 22.
6
FcRn Antagonism Leads to a Decrease of Desmoglein-Specific B Cells: Secondary Analysis of a Phase 2 Study of Efgartigimod in Pemphigus Vulgaris and Pemphigus Foliaceus.FcRn 拮抗剂导致桥粒芯糖蛋白特异性 B 细胞减少：以 Efgartigimod 在寻常型天疱疮和落叶型天疱疮的 2 期研究为基础的二次分析。
Front Immunol. 2022 May 18;13:863095. doi: 10.3389/fimmu.2022.863095. eCollection 2022.
7
A pathophysiological and mechanistic review of chronic inflammatory demyelinating polyradiculoneuropathy therapy.慢性炎性脱髓鞘性多发性神经根神经病治疗的病理生理学与机制综述
Front Immunol. 2025 Apr 14;16:1575464. doi: 10.3389/fimmu.2025.1575464. eCollection 2025.
8
Effects of efgartigimod treatment on humoral and cellular immune responses: analysis of T-cell-dependent antibody response in cynomolgus monkeys.艾加莫德治疗对体液和细胞免疫反应的影响：食蟹猴中T细胞依赖性抗体反应的分析。
J Immunotoxicol. 2025 Dec;22(1):2459934. doi: 10.1080/1547691X.2025.2459934. Epub 2025 Feb 13.
9
Effect of efgartigimod on muscle group subdomains in participants with generalized myasthenia gravis: post hoc analyses of the phase 3 pivotal ADAPT study.依氟鸟氨酸对全身型重症肌无力患者肌肉亚群的影响：III 期关键性 ADAPT 研究的事后分析。
Eur J Neurol. 2024 Jan;31(1):e16098. doi: 10.1111/ene.16098. Epub 2023 Oct 16.
10
Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.随机 2 期研究 FcRn 拮抗剂 efgartimod 在全身性重症肌无力中的作用。
Neurology. 2019 Jun 4;92(23):e2661-e2673. doi: 10.1212/WNL.0000000000007600. Epub 2019 May 22.
引用本文的文献
1
The changing landscape of primary autoimmune neuropathies.原发性自身免疫性神经病不断变化的格局。
Nat Rev Neurol. 2025 Sep 5. doi: 10.1038/s41582-025-01133-3.
本文引用的文献
1
Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial.皮下注射依氟鸟氨酸在慢性炎症性脱髓鞘性多发性神经病（ADHERE）患者中的安全性、耐受性和疗效：一项多中心、随机撤药、双盲、安慰剂对照、2 期临床试验。
Lancet Neurol. 2024 Oct;23(10):1013-1024. doi: 10.1016/S1474-4422(24)00309-0.
2
The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy: Implications for Complement-Targeted Therapies.补体系统在慢性炎症性脱髓鞘性多发性神经病中的作用：对补体靶向治疗的影响。
Neurotherapeutics. 2022 Apr;19(3):864-873. doi: 10.1007/s13311-022-01221-y. Epub 2022 Apr 4.
3
Neonatal Fc Receptor-Targeted Therapies in Neurology.神经疾病中靶向新生儿 Fc 受体的治疗方法。
Neurotherapeutics. 2022 Apr;19(3):729-740. doi: 10.1007/s13311-021-01175-7. Epub 2022 Jan 7.
4
Getting specific: targeting Fc receptors in myasthenia gravis.精准定位：重症肌无力中Fc受体的靶向作用
Nat Rev Neurol. 2021 Oct;17(10):597-598. doi: 10.1038/s41582-021-00547-z.
5
Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy.慢性炎症性脱髓鞘性多发性神经根神经病的诊治进展。
Lancet Neurol. 2019 Aug;18(8):784-794. doi: 10.1016/S1474-4422(19)30144-9. Epub 2019 May 7.
6
Deregulated Fcγ receptor expression in patients with CIDP.CIDP 患者中失调的 Fcγ 受体表达。
Neurol Neuroimmunol Neuroinflamm. 2015 Aug 20;2(5):e148. doi: 10.1212/NXI.0000000000000148. eCollection 2015 Oct.
7
Intravenous immunoglobulin in neurology--mode of action and clinical efficacy.静脉注射免疫球蛋白在神经病学中的作用机制和临床疗效。
Nat Rev Neurol. 2015 Feb;11(2):80-9. doi: 10.1038/nrneurol.2014.253. Epub 2015 Jan 6.
8
Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway.静脉注射丙种球蛋白通过一种新的 TH2 途径抑制炎症反应。
Nature. 2011 Jun 19;475(7354):110-3. doi: 10.1038/nature10134.
9
Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy.慢性炎症性脱髓鞘性多发性神经病中B细胞上抑制性Fcγ受体IIB表达受损。
Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4788-92. doi: 10.1073/pnas.0807319106. Epub 2009 Mar 4.
10
Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor.静脉注射免疫球蛋白通过FcRn受体介导抗血小板抗体清除增加。
Thromb Haemost. 2002 Dec;88(6):898-9.
Zotero 插件